Overview

4'-Thio-araC (Thiarabine) in Advanced Hematologic Malignancies

Status:
Completed
Trial end date:
2013-11-01
Target enrollment:
Participant gender:
Summary
The goal of this clinical research study is to find the highest tolerable dose of 4'-thio-araC (thiarabine) that can be given to patients with advanced blood cancer. The safety of this drug will also be studied and 2 different dose schedules will be tested.
Phase:
Phase 1
Details
Lead Sponsor:
M.D. Anderson Cancer Center
Collaborator:
Access Pharmaceuticals, Inc.
Treatments:
Cytarabine